NMDA receptor antagonists

NMDA receptor antagonists

Drugs used in the hope of improving the mental condition of people with Alzheimer's disease and delaying progress. An example is memantine (Ebixa).
References in periodicals archive ?
NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
8] It is reported that peripherally administered NMDA receptor antagonists are involved with antinociception and anti-inflammatory cascade.
Most conventional nonselective NMDA receptor antagonists, however, have been implicated in adverse effects including psychotomimetic effects, impairments of learning, memory, and dissociative anesthesia.
It is reported that treatment with NMDA receptor antagonists during early developmental stages leads to an increase both in locomotor activity and exploratory behaviors [18-20]; however, in our study there was a decrease in the locomotor activity and exploratory behaviors.
The main adjuvant agents that are currently associated to opioids in the management of pain are NMDA receptor antagonists, [[alpha].
Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.
30, 31) Analogously, studies have indicated that glutamate plays crucial roles in the initiation, spread, and maintenance of epileptic activity, (32, 33) and NMDA receptor antagonists have anticonvulsant activity.
65-67] The notion that involvement of both the hippocampal and amygdaloid NMDA receptors in fear conditioning is supported by several studies which report that intra-amygdala or hippocampal infusions of the NMDA receptor antagonists APV or MK-801 effectively block both the acquisition and expression of fear conditioning.
NMDA receptor antagonists, MK-801 and ACEA-1011, prevent the development of tonic pain following subcutaneous formalin.
NMDA receptor antagonists represent an alternative mechanism that has the potential to improve depression in patients resistant to conventional antidepressants.
Attenuation of glutamate-induced neurotoxicity in chronically ethanol-exposed cerebellar granule cells by NMDA receptor antagonists and ganglioside GM l.
The topics include studies of noncompetitive NMDA receptor antagonists, systemically active antagonists at the NMDA glycine site, AMPA and NMDA antagonists that are active in vivo, antagonists of group I metabotropic glutamate receptors, and AMPA antagonists for therapy of stroke and trauma.